DHFR and cancer: Three pharmacodynamic attributes of pyrimethamine recommend its use in disseminated human cancer: (1) inhibition of human dihydrofolate reductase (DHFR), (2) inhibition of thymidine phosphorylase, and (3) inhibition of STAT3.